Actively Recruiting
Phase 1 Study to Evaluate How Itraconazole Affects ABBV-722 in Healthy Adults Aged 18 to 65
Led by AbbVie · Updated on 2026-05-20
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how repeated doses of the drug itraconazole affect the way a single dose of ABBV-722 is processed in the body. This Phase 1 study is conducted in healthy adult volunteers to better understand the interaction between these two drugs and their safety and tolerability. The study focuses on detailed measurements of ABBV-722 in the blood after administration with and without itraconazole. The study consists of two periods. In Period 1, participants receive a single dose of ABBV-722 alone. In Period 2, participants take multiple daily doses of itraconazole along with a single dose of ABBV-722. Both drugs are given orally as tablets or capsules. This design allows comparison of ABBV-722 levels in the body with and without itraconazole to observe any changes in drug processing. Participants will have blood samples collected up to day 8 in Period 1 and up to day 14 in Period 2 to measure ABBV-722 concentrations, including peak levels, timing, and overall exposure. Researchers will also monitor for any adverse events up to approximately 45 days. Assessments include medical history, physical exams, vital signs, lab tests, and ECGs to ensure safety throughout the study. The total participation time covers both study periods and follow-up evaluations.
CONDITIONS
Brief Title
A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
